Boulder, Colorado - August 23, 2007 - Bolder BioTechnology, Inc. is pleased to announce that it has been granted patent 7,253,267 by the U.S. Patent and Trademark Office. Joe Cox, Company President commented “This patent provides key intellectual property protection for our long-acting, second generation interleukin-11 (IL-11) analog product. IL-11 is a human protein that stimulates bone marrow cells to divide and differentiate into platelets, which are important components of the blood clotting system. Recombinant IL-11 is approved for use in cancer patients whose platelet levels have fallen to dangerous levels as a side effect of their chemotherapy treatments. Many cancer patients are forced to stop or delay receiving chemotherapy treatments due to low platelet levels, which can adversely affect treatment outcome. Preclinical studies indicate that a single injection of our long-acting IL-11 analog increases platelet levels for over a week in animals, whereas the current commercial IL-11 product requires multiple daily injections to increase platelets to similar levels. These data encourage us to believe that our long-acting IL-11 analog may provide cancer patients with a more convenient and potentially more effective and safer treatment option for combating one of the most common dose-limiting side effects of chemotherapy. This product also may prove useful for treating other diseases characterized by low platelet levels, such as myelodysplastic syndrome.”
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. Research leading to the development of the Company's long acting Interleukin-11 analogs has been supported by Small Business Innovation Research (SBIR) grants awarded to Bolder BioTechnology by the National Cancer Institute of the National Institutes of Health. For additional information about Bolder BioTechnology, Inc., please visit our web site at www.bolderbio.com.
Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.
Contact information: Joe Cox, Ph.D., President (303) 420-4420 ext.202